Supplementary Material 6: Sensitivity analyses.

Figure 1: Prevalence of MG infection among PrEP users, estimated with Freeman-Tukey double arcsine as the transformation method for prevalence estimates.

Study	MG+	n		Prevalence	95%CI			
Point prevalence			1					
Berçot et al., 2021	22	210		10.48	[6.68; 15.43]			
Bradley et al., 2020	20	170		11.76	[7.34; 17.58]			
Brin et al., 2022	52	207		25.12	[19.37; 31.60]			
Chambers et al., 2019	7	18		> 38.89	[17.30; 64.25]			
Couldwell et al., 2018	33	169		19.53	[13.84; 26.31]			
De Baetselier et al., 2022	2 31	179		17.32	[12.08; 23.67]			
Deborde et al., 2019	9	89	-+	10.11	[4.73; 18.33]			
Herms et al., 2021	2	13		15.38	[1.92; 45.45]			
Jansen et al., 2020	55	283		19.43	[14.99; 24.53]			
McIver et al., 2019	14	102		13.73	[7.71; 21.96]			
Read et al., 2019	16	142		11.27	[6.58; 17.65]			
Streeck et al., 2022	· · -	553		20.25	[16.98; 23.85]			
Random effects model	2	2135	\diamond	16.22	[13.08; 19.61]			
Prediction interval					[6.88; 28.33]			
Heterogeneity: I ² = 70%								
Period prevalence (6 months)								
Berçot et al., 2021	32	210		15.24	[10.66; 20.83]			
Period prevalence (12 r	nonthe)							
Van Praet et al., 2020	27	131		20.61	[14.04; 28.55]			
Val 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	21	101		20.01	[14.04, 20.00]			
Period prevalence (18 r								
De Baetselier et al., 2022	2 70	179		39.11	[31.91; 46.67]			
Period prevalence (24 r	nonths)							
Ducours et al., 2019	28	148		18.92	[12.95; 26.17]			
2400410 0t al., 2010	20	. 10		7	[.2.00, 20.17]			
			0 10 20 30 40 50	60				

Figure 2: Prevalence of macrolide-resistant MG infection among PrEP users, estimated with Freeman-Tukey double arcsine as the transformation method for prevalence estimates.

Macro	lide resistant	:			
Study	MG+	n		Prevalence	95%CI
Point prevalence			1		
Couldwell et al., 2018	26	33		78.79	[61.09; 91.02]
McIver et al., 2019	12	14		85.71	[57.19; 98.22]
Read et al., 2019	16	16		100.00	[79.41; 100.00]
Random effects model		63		90.01	[71.65; 99.89]
Prediction interval Heterogeneity: $l^2 = 67\%$		•	-	•	[0.00; 100.00]
Period prevalence (6 months) Berçot et al., 2021	16	23		69.57	[47.08; 86.79]
Period prevalence (9 months) Guiraud et al., 2021	12	16		75.00	[47.62; 92.73]
Period prevalence (24 months Ducours et al., 2019) 21	28		75.00	[55.13; 89.31]
			0 20 40 60 80 1	00	